Ab­b­Vie’s PARP in­hibitor floun­ders in PhII as ri­vals surge ahead in late-stage dri­ve

Ab­b­Vie’s PARP in­hibitor veli­parib failed two key end­points in a Phase II study of metasta­t­ic breast can­cer with BR­CA1 or BR­CA2 mu­ta­tions.

In­ves­ti­ga­tors, in­clud­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA